FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS

1 . A pharmaceutical composition, comprising:

(a) particles comprising

(i) dasatinib in an amount of about 10% by weight to about 70% by weight of the particles; and

(ii) at least one polymeric stabilizing and matrix-forming component;

(b) at least one disintegrant agent in an amount of about 4% by weight to about 16% by weight;

(c) at least one gas generating agent in an amount of about 8% by weight to about 22% by weight; and

(d) at least one acidic pH modifier in an amount of about 2% by weight to about 6% by weight.

2 . The pharmaceutical composition of claim 1 , wherein the particles are solid dispersion particles.

3 . The pharmaceutical composition of claim 1 , wherein dasatinib is 100% amorphous.

4 . The pharmaceutical composition of claim 1 , wherein the gas generating agent is selected from a group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium sulfite, potassium sulfite, an ammonium cation, and a combination thereof.

5 . The pharmaceutical composition of claim 1 , wherein the gas generating agent is selected from a group consisting of sodium bicarbonate, potassium bicarbonate, and a combination thereof.

6 . The pharmaceutical composition of claim 1 , wherein the acidic pH modifier is selected from a group consisting of sorbic acid, adipic acid, succinic acid, fumaric acid, tartaric acid, and a combination thereof.

7 . The pharmaceutical composition of claim 1 , wherein the mole ratio of the gas generating agent to the acidic pH-modifier ranges from about 4:1 to about 1:4.

8 . The pharmaceutical composition of claim 1 , wherein the disintegrating agent comprises crospovidone.

9 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises dasatinib in an amount of about 15 mg, about 36 mg, about 50 mg, about 57 mg, about 70 mg, or about 100 mg.

10 . A method of treating a disorder in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 1 to the patient, wherein said proliferative disorder is newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;

adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib; and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

11 . The method of claim 10 , wherein an amount of dasatinib in the pharmaceutical composition comprises 15 mg, 36 mg, 50 mg, 57 mg, 70 mg, or 100 mg.

12 . The method of claim 10 , wherein a dasatinib dose of X achieves bioequivalence to a dasatinib dose of Y for Sprycel, wherein X and Y are respectively selected from (i) 15 mg (X) and 20 mg (Y), (ii) 36 mg (X) and 50 mg (Y), (iii) 50 mg (X) and 70 mg (Y), (iv) 57 mg (X) and 80 mg (Y), (v) 70 mg (X) and 100 mg (Y), and (vi) 100 mg (X) and 140 mg (Y).

13 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL.

14 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides an AUC(0-09) of about 877 ng·hr/mL

15 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL and an intersubject coefficient of variation of about 12%.

16 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL and an intrasubject coefficient of variation of about 29%.

17 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides an AUC(0-∞) of about 877 ng·h/mL and an intersubject coefficient of variation of about 9%.

18 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides an AUC(0-∞) of about 877 ng·h/mL and an intrasubject coefficient of variation of about 14%.

19 . The method of claim 10 , wherein a dasatinib dose of 100 mg provides an AUC (0-24 h) fed/AUC (0-24 h) fasted ratio of from about 95% to about 100%, wherein AUC (0-24 h) fed corresponds to the least-squares geometric mean of the AUC (0-24 h) in fed patients and wherein AUC (0-24 h) fasted corresponds to the least-squares geometric mean of the AUC (0-24 h) in fasted patients.

20 . The method of claim 10 further comprising co-administering a gastric acid reducing agent (ARA) comprising antacid, an H2 antagonist, or a proton pump inhibitor.

21 . The method of claim 20 , wherein the gastric acid reducing agent is administered shortly before the pharmaceutical composition is administered.

22 . The method of claim 20 , wherein the gastric acid reducing agent is administered shortly after the pharmaceutical composition is administered.

23 . The method of claim 20 , wherein the gastric acid reducing agent is administered concurrently with the pharmaceutical composition.

24 . A pharmaceutical composition in the form of a tablet, comprising:

(a) an amorphous solid dispersion comprising dasatinib in an amount of from about 17% w/w to about 21′)/0 w/w and copovidone in an amount of from about 38% w/w to about 42% w/w;

(b) mannitol in an amount of from about 11% w/w to 15% w/w;

(c) sodium bicarbonate in an amount of from about 10% w/w to about 14% w/w;

(d) crospovidone in an amount of from about 6% w/w to about 10% w/w;

(e) fumaric acid in an amount of from about 2% w/w to about 6% w/w;

(f) sodium stearyl fumarate in an amount of from about 0.1% w/w to about 4% w/w; and

(g) colloidal silicon dioxide in an amount of from about 0.1% w/w to about 1′)/0 w/w;

wherein the stated amounts are based on the total weight of the composition; and

wherein the tablet optionally comprises a coating layer.

25 . The pharmaceutical composition of claim 24 , comprising dasatinib in an amount of from 19% w/w to 20% w/w;

copovidone in an amount of from 39% w/w to about 40% w/w;

mannitol in an amount of from about 12% w/w to 14% w/w;

sodium bicarbonate in an amount of from 11° A w/w to 13% w/w;

crospovidone in an amount of from 8% w/w to 9% w/w;

fumaric acid in an amount of from 4% w/w to about 5% w/w;

sodium stearyl fumarate in an amount of from about 2% w/w to about 3% w/w; and

colloidal silicon dioxide in an amount of from about 0.4% w/w to about 0.6% w/w;

wherein the stated amounts are based on the total weight of the composition and

wherein the tablet optionally comprises a coating layer.

26 . The pharmaceutical composition of claim 24 , comprising

dasatinib in an amount of about 19% w/w;

copovidone in an amount of about 40% w/w;

mannitol in an amount of about 13% w/w;

sodium bicarbonate in an amount of about 12% w/w;

crospovidone in an amount of about 8% w/w;

fumaric acid in an amount of about 4.5% w/w;

sodium stearyl fumarate in an amount of about 2.5% w/w; and

colloidal silicon dioxide in an amount of about 0.5% w/w;

wherein the stated amounts are based on the total weight of the composition and

wherein the tablet optionally comprises a coating layer.

27 . A method of treating a disorder in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 24 to the patient, wherein said proliferative disorder is newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

28 . The method of claim 27 , wherein an amount of dasatinib in the pharmaceutical composition comprises 15 mg, 36 mg, 50 mg, 57 mg, 70 mg, or 100 mg.

29 . The method of claim 27 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL, an AUC(0-∞) of about 877 ng·hr/mL, or a combination thereof.

30 . The method of claim 27 , further comprising co-administering a gastric acid reducing agent (ARA) comprising antacid, an H2 antagonist, or a proton pump inhibitor.